Catherine Calarco
Company Image:  (Source: EyeForPharma)
Source: EyeForPharma - March 6, 2019 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Automation Is Here To Stay … Hip Hip Hooray!
“Success is the ability to go from one failure to another with no loss of enthusiasm.” So said Winston Churchill, who noted that persistence was not a universal quality amongst his peers. “Never give up.”The problem is, humans are ill-prepared to approach a situation for the hundredth or millionth time without at least facing some dip in performance. The answer is automation, a growing trend in digital investments and one which has recently entered the pharmaceutical industry. Computers can try and try again, with just as much fervor as with the first attempt.Despite this obvious advantage, whe...
Source: EyeForPharma - February 26, 2019 Category: Pharmaceuticals Authors: Catherine Calarco Source Type: news

The future of patient services
Channels: Access and EvidenceMedicalMultichannelPatients and MedicalImage: URL: http://bit.ly/2BuzY1BExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - February 11, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

RWE: The Missing Link
This article is from our latest'Trends in Real-World Evidence'magazine.  Download for free.Data linkage challenges Linking data is not an easy process; not only does it require the right technological tools and knowhow, it raises a range of concerns, from patient anonymity and data ownership, to how to transcend geographical barriers.Anonymizing data is a fundamental challenge, says Nigel Hughes, Scientific Director at Janssen Clinical Innovation – Patient Data for Research. “Data linkage requires, via an underlying consent model, linking different data together – with the patient being the common l...
Source: EyeForPharma - January 7, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

What Can Pharma Expect in 2019?
For those of us that use the Gregorian calendar, this time of year is one for reflection. We look back at the year just gone and forward to the year to come and, armed with a list of best-self resolutions, we step into January full of hope and intention.Like most years, 2018 was a busy one for the pharmaceutical industry – best characterized perhaps not as a year of radical change but as 12 months of under-the-surface action. (But if you disagree,please do let me know).To this editorial team it appears that companies are starting to get to grips with some of the big trends that have swept the industry over the past f...
Source: EyeForPharma - January 7, 2019 Category: Pharmaceuticals Authors: The eyeforpharma Editorial Team Source Type: news

Gold standard: Standardizing RWD
Within healthcare circles, the hype around the potential of real-world evidence to transform health outcomes through new patient insights has been considerable.But as the pool of RWD swells daily – driven by growing demand from drug development, regulatory decision-making and patient care and enhanced by advances in technology, study design and data collection methods – there is one very large stumbling block on the horizon.“As data is collected in multiple languages, formats, ontologies, structures, and platforms, you end up with a Tower of Babel challenge,” says Nigel Hughes, Scientific Director, ...
Source: EyeForPharma - January 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Leading the Charge
Imagine being a freshman at college on a basketball scholarship. You know this scholarship is your ticket out of your small mining town and on to a brighter future. Now imagine being told that you might lose your foot due to a misdiagnosis of an ankle injury.That is exactly what happened to Frank Washenitz, now VP, Head of Global and NA Sales Enhancement at Mylan. Luckily for Frank, he did not lose that ankle. The experience, however, left him sensitive to the fragility of health, the need for improvement in medicine and a desire to make a difference.“Looking back, I never really had a plan to be in pharma training, ...
Source: EyeForPharma - December 14, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Growing Pains
There is no one-size-fits-all model for pharma companies seeking input from patients. There was no blueprint when companies took their first tentative steps a few years ago and there is none now as they enter the next era – scaling up patient-centric efforts to become business as usual.“When I talk to patient organizations, many times they ask, Why does wanting better patient outcomes require a culture shift in pharma?” says Laura McKeaveney, Head of Global Patient Advocacy at Novartis. “But that’s not what requires the culture shift.”People who work in pharma want better patient outcome...
Source: EyeForPharma - December 12, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

VBCs: Are They Working?
As an observer, it can be difficult to find out what ’s happening with value-based contracts (VBCs). The fanfare that accompanies the announcement of a deal invariably gives way to a long period of silence, a good sign if you subscribe to the mantra that no news is good news, but if you don’t, there is cause for concern.The smattering of reports on the topic suggest that green shoots are emerging. A recent survey of 120 payers conducted by the ORC International and commissioned by Change Healthcare, found that payers reported an average saving in medical costs of 5.6% from VBC strategies with an accompanying 77...
Source: EyeForPharma - December 12, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Made to Measure
Often attributed to management guru Peter Drucker but perhaps coined first by 19th century scientist William Thompson, Lord Kelvin, there is more to this famous quotation than first meets the eye.On the one hand, it is common sense – you do, you measure, you improve. But, on the other hand, can your activity be measured? Do the tools and metrics even exist? And, are you measuring the right things? Measuring can be a tricky business.Patient-centricity has transformed pharma, yet few companies effectively measure the impact of their patient engagement activities let alone track the shift in their people towards a patie...
Source: EyeForPharma - December 11, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

Calling the Shots?
The USA has the highest drug costs in the world, and they are increasing at the fastest rate too. With one in five Americans saying they have been forced to leave a prescription unfilled due to high costs, the situation is clearly unsustainable.Payers and pharmacy benefit managers (PBMs), themselves facing increased criticism for blocking access to important medicines, are taking action by demanding that pharma companies justify the cost – and value – of their new medicines.“There is a point where a government, an employer or a healthcare plan has a finite amount of resources to spend,” says Brian H...
Source: EyeForPharma - December 10, 2018 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Cutting Out the Middleman
In the war on drug prices, the middleman is in everyone ’s sights.Announcing his American Patients First blueprint earlier this year, President Trump said one of his “greatest priorities” was to reduce the price of prescription drugs. He added that a key element in delivering this ambition was “very much eliminating” the middlemen.“The middlemen became very, very rich. Whoever those middlemen were – and a lot of people never even figured it out – they’re rich. They won’t be so rich anymore,” he said.While neither the president nor the blueprint itself actual...
Source: EyeForPharma - December 7, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

An Impatient Truth
15 years ago, I introduced the concept of patient centricity at our first ‘Patient Summits’ in London and Philadelphia. At the time, the idea was somewhat alien; pharmaceutical executives were more interested in patient compliance, the science of getting patients to take their medicine as instructed, and driving sales through repeat prescriptions.The existing language of the day was aggressive. It was all about ‘capturing’ market share and ‘dominating’ the minds of customers. I’ll never forget being berated by one delegate because a conference talk had deviated from the agenda &nda...
Source: EyeForPharma - November 9, 2018 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

Adherence webinar
Channels: CommercialImage: URL: https://www.eyeforpharma.com/philadelphia/webinar5/?partner=efp-websiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 18, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Tech For The Over-65s
People are living better for longer than ever before, and research has consistently shown that the longer one stays independent in one ’s own home, the happier and healthier one is.[1] There is a clear societal need to meet the practical and emotional burdens of aging in a fast-growing low-dependence group whose quality of life could be transformed with the right level of light-touch care.  Pharmaceutical and healthcare players big and small are currently exploring how best to support over-65s in maintaining quality of life. Digital health technology to support patient quality of life is taking hold, and smartph...
Source: EyeForPharma - October 18, 2018 Category: Pharmaceuticals Authors: Pamela Walker Source Type: news

Working with HTAs: It ’s Your Move
In June last year, the heads of European health technology assessment (HTA) bodies came together at a meeting facilitated by EUnetHTA (European Network for Health Technology Assessment) and the European Commission ’s Directorate General for Health and Food Safety.A key focus of the event was the creation of earlier and more engaging dialogue between pharma and HTA bodies. This is not surprising. As critical gatekeepers for new medicine seeking access to national markets, HTAs are playing central roles in moves to tighten control over drug spending across Europe. As part of this, bodies are going further than ever bef...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news

Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping po...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news

Can Payers Trust Our Data?
The potential for real-world data to be used on a mass scale to demonstrate the effectiveness and value of medicines is great, promising benefits for all parties including better health outcomes and lower premiums for patients and higher prices for those selling the most effective treatments.Yet, while the use of real-world evidence is growing, a major impediment to its broader and faster adoption is the potential trust gap. After all, how can payers be sure that pharma ’s data tell a true and accurate story about patient outcomes?Payers are increasingly questioning the data they are provided with, says Michelle Hois...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Diving for Data
Discussion around this is definitely part of the public discourse now but this is going to turn slowly like an ocean liner as incentives become more aligned.“The reimbursement of volume-based agreements is such a complex calculation to unwind, and people acknowledge that it is sensible but a hard thing to do. It takes a lot to move people off tried-and-true, low-risk ways of measuring the performance of a drug.Related Content: Rid Yourself Of Dirty DataTalking The Same LanguageNavigating the ChaosSeeking the Holy Grail of RWEThe Naked Truth About Outcomes-Based PricingPrimary Event: Value Summit USA 2018Pr ...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Partnership Is Key To Better Patient Programs
Online shoppers do not struggle when using Amazon or eBay. Over the last 20 years, ecommerce providers have coalesced around a common set of tools to help shoppers find what they want.As the healthcare sector focuses on developing digitized patient support programs, it needs to understand how a similar sense of usability will emerge.At arecent webinar, organized by eyeforpharma and S3 Connected Health, we polled 234 participants to understand how they see patient support programs (PSPs) developing.It is clear the stakes are high; 40% said they were'a significant way to make medicine more holistic', while 38% said PSPs woul...
Source: EyeForPharma - October 15, 2018 Category: Pharmaceuticals Authors: Jim O ' Donoghue Source Type: news

Agility WP
Channels: CommercialImage: URL: https://eloqua.eyeforpharma.com/LP=22351?extsource=efp_social&utm_source=efp%20website&utm_medium=banner&utm_campaign=4987&utm_content=AgileExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 11, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Authentic medical affairs Whitepaper
Channels: MedicalImage: URL: https://eloqua.eyeforpharma.com/LP=22334?extsource=efp_website&utm_source=efp%20website&utm_medium=banner&utm_campaign=4987&utm_content=AuthenticExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 11, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Obc wp
Channels: Access and EvidenceImage: URL: https://eloqua.eyeforpharma.com/LP=22276?extsource=linkedin_adExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 5, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Digital Therapeutics: Pharma's Threat or Opportunity?
Channels: Patients and MedicalClinicalColumnCommercialImage: URL: http://bit.ly/2Taaf4mExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 3, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Eyeforpharma awards 2019
Channels: Patients and MedicalImage: URL: http://bit.ly/2Ni4qPiExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 3, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Data Ownership Is Having Its Moment
Fear of change is a powerful force. Many believe that if something truly novel is created, something existing must die. It ’s as if innovation is a zero-sum game.Change can be disruptive and expensive, but there are some precious times when change – or rather evolution – can be purely constructive.The marketplace for the data of individual healthcare consumers is broken. It ’s unsustainable, unfriendly and everyone knows that sooner or later it must change. That change can come through lawsuits and legislation or by the healthcare industry proactively embracing a new system design that is a win-win ...
Source: EyeForPharma - September 26, 2018 Category: Pharmaceuticals Authors: Richie Etwaru Source Type: news

Would Your Reps Pass The Empathy Test?
Make no mistake about it, the role of the pharmaceutical sales representative is in flux. But, then, when has it not been?In truth, looking at today ’s small, data-fueled sales forces, it’s hard to conceive that back in the early nineties more than 100,000 pharma reps were plying their trade in the US alone.Back then, the name of the game was – in reductive terms – to flog as many blockbuster drugs to healthcare professionals (HCPs) as possible. Ok, it was always much more nuanced than that, but it never approached the complexity of today’s environment, where reps are increasingly expected to ...
Source: EyeForPharma - September 19, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news

Why CX Starts in Sales
A quicker starter for ten: What is customer experience?It ’s a question that foxes many, but if there is one role in pharma that needs no definitions – who know what CX is instinctively – it is the sales rep.In its simplest terms, CX is a series of interactions between customer and organization over the course of a business relationship, but it ’s reach is far broader and deeper. CX is at once transactional and emotional; an individual or entity either forms a favorable enough impression to continue giving their custom to a respective company or they try their chances elsewhere.As the concept of CX ...
Source: EyeForPharma - September 18, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news

The Best Job in Pharma Right Now? The Sales Rep
Every business likes to believe that it knows its customers. We know who and where they are, what they like and what they don ’t, and, most important of all, what they need.In the past, we relied on anecdotal evidence and gut feeling, more recently on market research and segmentation. But now, as the data trickle swells to a torrent and the digital revolution continues to transform our lives and our expectations, customers are seeking a fundamentally different, more personalized and evidence-based relationship.The pharmaceutical sales force lies at the epicenter of this seismic shift.Sales reps carry an incredibly va...
Source: EyeForPharma - September 15, 2018 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Trends in Pharma Sales
Channels: CommercialImage: URL: http://1.eyeforpharma.com/LP=22033?extsource=efp_linkedin&utm_source=efp%20website&utm_campaign=4987&utm_content=Sales%20MMExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - September 13, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Real-World Medical Affairs
Channels: MedicalImage: URL: https://www.eyeforpharma.com/medicalaffairsusa/webinar2/?partner=efp-Website&utm_source=efp%20banner&utm_medium=banner&utm_campaign=4987Exclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - August 25, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Why Patient Organizations Are No Summer Fling For Pharma
Breaking news: Protestors from patient organizations gather en masse outside a pharmaceutical company ’s headquarters wielding placards emblazoned with the words TRANSACTIONAL and TOKENISTIC.Not too long ago, such an event might have been plausible given the pharma industry ’s checkered history with patient organizations. The criticism often levelled at the industry is that patient groups are merely used as props in the marketing machinery; endorsing the latest product launch before being unceremoniously dropped.Times have changed, however. In an ongoing bid to better engage and understand patients, pharma is t...
Source: EyeForPharma - August 8, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Going Through the Motions
If the pharma industry got a dollar for every time it talked about improving relationships with payers, it probably wouldn ’t have a grave pricing challenge on its hands.Looking at it rationally, there is a clear win-win from greater harmony – pharma understands in advance the concerns of payers and can adjust its strategy to ensure effective market access, while payers get a heads-up on drugs are coming through and what impact they will have, and can plan budgets ahead.Yet, the reality is somewhat different. Collaboration – the word de jour for pharma in this decade – does not come easily, and many...
Source: EyeForPharma - August 6, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Navigating the Chaos
" If you ’re not confused, you’re not paying attention.”This quote from best-selling author and business guru Tom Peters ’Thriving On Chaos could have been written for pharma right now.Megatrends disrupt the landscape, while political and economic uncertainties make predicting the future a fool ’s game. Chaos is everywhere, not least in patient access.How companies respond may well have a lot to do with that eternal question – is the glass half-full or half-empty?“I like the uncertainty that chaos brings in filling up that glass,” says John A. Bardi, VP, Public Affairs a...
Source: EyeForPharma - August 6, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Flying The Flag For Patients
Patient-centricity rose like a phoenix from the ashes of the blockbuster era. After decades of focus almost entirely on the prescription pads of physicians (we even supplied the pens!), it was only a handful of years ago that pharma companies felt the winds of change on their faces. Many tacked to catch those winds in their sails.However, turning a vessel as large and unwieldy as a multinational corporation is no easy task. Getting sales reps, marketers, medical affairs, health economists, clinicians, scientists and senior managers to stop asking, What do HCPs need? and start asking, What do patients need? was always going...
Source: EyeForPharma - August 2, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

Seeking the Holy Grail of RWE
Billion-dollar acquisitions tend to make a lot of noise. Markets react, competitors get jittery and share prices can spike or tumble.When Roche bought Flatiron Health, a tech platform that captures and synthesizes structured and unstructured oncology data, for $1.9 billion back in February, it sent tremors throughout the healthcare industry.The ripple effect cannot be chalked up to corporate muscle-flexing however. The deal sent an unequivocal message that the time has come to establish a regulatory-grade standard for real-world evidence.Commenting on the tie-up, Roche ’s CEO said, “This is an important step in...
Source: EyeForPharma - August 2, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Achieve value-based contracting - true partnerships with patients for improved data quality and outcomes
Channels: Access and EvidenceImage: URL: https://www.eyeforpharma.com/rwe/webinar3/?partner=efp-WebsiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - July 31, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Five Reasons Why Clinical Trials Fail And What Pharma is Doing To Fix It
If echo chambers, polarizing politics and solipsism sums up the world in 2018, the art of listening has become gold dust.The pharma industry appears to be bucking the trend however. When it comes to the patient voice, companies are becoming all ears, with patient insights driving internal decisions across the board.We decided to put this proposition to the test.One of pharma ’s perennial thorns is clinical trial recruitment. 86% of clinical trials do not reach recruitment targets within their specified time periods. Patients clearly have their grievances but are pharma companies truly listening? More importantly, are...
Source: EyeForPharma - July 27, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Six Ways Artificial Intelligence Is Impacting Patients
It ’s difficult to open a newspaper nowadays without seeing an article about artificial intelligence. These column-inches spark our imaginations with heady visions of possible futures and crease our brows with concern in equal measure. But one thing you cannot escape is that AI is here now and it’s only going to become more pervasive.While fear of an unknown technology is understandable, in many ways it does a disservice to the incredible impact that AI is already having on the world around us. In the healthcare space alone, it is offering ways to fundamentally rethink clinical practice, speeding up diagnosis, ...
Source: EyeForPharma - July 24, 2018 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Tackling Stigma
Sadly, stigma around health conditions remains a part of many patients ’ lives. Many will not disclose a diagnosis for fear of being judged by peers, employers, health professionals, colleagues and wider society. In fact, there is clear evidence that such negative societal attitudes impact health outcomes, resulting in diagnosis delays and impaired treatment.Some diseases are heavily stigmatized – including mental health, HIV/AIDS, hepatitis and some skin conditions – leading people to restrict their participation in society, impairing their chances of living happy, healthy lives.However, to one extent or...
Source: EyeForPharma - July 17, 2018 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

In Search of Pharma ’s Moore’s Law
Artificial Intelligence (AI) has made great strides in the past five years. We are probably using an AI-based system without even realizing it in our daily lives today. There is a lot of active research going on in AI in both academia and in the pharma industry. Within pharma, several opportunities open up as we think of AI making an impactful difference; lead candidate identification, drug development, compound repurposing, clinical trials, post approval, commercial markets, etc. Let us look at one area closely, that of planning and conduct of clinical trials.Costs of bringing a drug to the market over the last three deca...
Source: EyeForPharma - July 5, 2018 Category: Pharmaceuticals Authors: Sagar Anisingaraju Source Type: news

The Highs and Lows of Healthcare
Every once in a while, I meet someone who I think should be the ‘patient-centric poster child’.This person is doing great work advancing their organization ’s efforts to create better outcomes for patients (and so better outcomes for their company and people). In the spirit of illuminating our path to patient-centricity, growing together faster than any of us can alone, this column is dedicated to sharing their stories, successes and challenges.Doug Noland, Head Patient Experience, Executive Director, Astellas US, shares why he is on a mission to create a culture of patient-centricity and loving it.Before...
Source: EyeForPharma - July 5, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

First, We Need To Talk: Mental Healthcare In The MENA Region
The Middle East and North Africa (MENA) face daunting challenges in managing a growing burden of mental illness, often in adverse conditions that can leave their imprint on generations to come.While the burden of mental-health conditions is above the global average in most MENA countries, the human resources, policies, funding and infrastructure to deal with these problems are sorely lacking.According to a recent study led by the Institute for Health Metrics and Evaluation (IHME), mental disorders excluding substance abuse accounted for 4.7% of all disability-adjusted life years (DALYs) in the World Health Organization &rs...
Source: EyeForPharma - July 5, 2018 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

Becoming the #1 Partner to Patient Groups
“We don’t partner with patient groups to have a good reputation,” says Amy Nicole Nayar, Head of Global Patient Relations at Abbvie. “If you want to partner with patient groups to improve your reputation, you will miss the mark.” An authentic intention to improve patient outcomes is the key factor to success.  We all want to be patient-centric, says Nayar. “There’s a reason why we all come to this industry,” she says.For her, it ’s personal – she grew up with a brother who had epilepsy and received an innovative treatment. Although it didn’t change...
Source: EyeForPharma - June 15, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Where Next For Digital Support Programs?
Is the pharma business model broken? How will pharma firms deliver true value and relevance in the years ahead? What is the step change required?These questions were at the back of my mind when S3 Connected Health and eyeforpharma were working on our joint white paper,Patient Support Programs: Now, Near, Next. We wanted to take the pulse of industry experts on their ‘beyond the pill’ strategy, so we spoke to 20+ senior leaders currently designing and implementing patient support programs (PSPs) from firms including Novartis, AstraZeneca, Sanofi and Takeda.All are mindful of the wider context; hugely expensive d...
Source: EyeForPharma - June 15, 2018 Category: Pharmaceuticals Authors: Jim O ' Donoghue Source Type: news

Data Analytics: The New Gold Standard In Drug Value
Conclusion The fundamental shift underway is in the use of data analytics as a strategic foundational layer, asking what insights are needed to assist in more informed decision making, driving data points to include during the development of new treatments.The following four elements are essential for drug developers to realize the benefits of this new approach: Put data analytics at the center of strategic thinking and augment conclusions with KOL input, rather than the other way around. Empower development around patient insights derived from carefully designed data-analytics. Focus on discovering patient value rath...
Source: EyeForPharma - May 30, 2018 Category: Pharmaceuticals Authors: Preeti Patel and Sophie Schmitz Source Type: news

know your customer
Channels: MultichannelPatients and MedicalImage: URL: https://goo.gl/R9FKZxExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - April 25, 2018 Category: Pharmaceuticals Authors: Andy Robertson Source Type: news

The rep of tomorrow today
Channels: MultichannelImage: URL: https://goo.gl/RztynaExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - April 25, 2018 Category: Pharmaceuticals Authors: Andy Robertson Source Type: news

Achieving Success in Emerging Markets
In developed countries, the quality of medicines is consistently good – regardless of whether a medicine is an original formulation or generic – due to long-standing and strict quality regulations. However, this is not always the case in emerging markets, where access to reliable, quality medicines has been inconsistent historically.The situation is changing, and many emerging markets are implementing stricter guidelines. In 2017, the World Health Organization said one-in-ten medicines in low-and middle-income countries were found to be substandard or falsified, an improvement on one-in-four in 2007.Beyond qual...
Source: EyeForPharma - April 16, 2018 Category: Pharmaceuticals Authors: Andrew Lane Source Type: news

Working Together Wins The Day
If the constant talk about collaboration reflects an awkward truth, it ’s that pharma’s silos too often silence the patient voice and stymie progress. Today, Jen Horonjeff was named this year's Patient Advocate for her efforts in breaking down these barriers — both in her personal and professional life — at eyeforpharma’s annual Philadelphia event.She praised the Patient Advocate award for shining a light on the value that comes from collaborating with patients to co-create solutions, and for recognizing the efforts that are happening outside of the industry.“It is such an honour to win ...
Source: EyeForPharma - April 11, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news